Evaluation of the BBL MGIT (Mycobacterial growth indicator tube) AST SIRE system for antimycobacterial susceptibility testing of Mycobacterium tuberculosis to 4 primary antituberculous drugs

• Published in: Archives of pathology & laboratory medicine (1976) Vol. 124; no. 1; pp. 82 - 86
• Main Authors: Bergmann, J S, Fish, G, Woods, G L
• Format: Journal Article
• Language: English
• Published: United States College of American Pathologists 01.01.2000
• Subjects: Antitubercular Agents - pharmacology; Disease control; Drugs; Ethambutol - pharmacology; Evaluation Studies as Topic; Humans; Isoniazid - pharmacology; Laboratories; Methods; Microbial Sensitivity Tests - methods; Mycobacterium tuberculosis - drug effects; Mycobacterium tuberculosis - growth & development; Performance evaluation; Reproducibility; Reproducibility of Results; Rifampin - pharmacology; Streptomycin - pharmacology; Tuberculosis; United States > US
• ISSN: 0003-9985; 1543-2165
• DOI: 10.5858/2000-124-0082-EOTBMM

To evaluate the performance of the BBL MGIT (Mycobacterial Growth Indicator Tube) AST SIRE system for the antimycobacterial susceptibility testing of Mycobacterium tuberculosis to isoniazid (at a concentration equivalent to the lower concentration used for testing by the method of proportion), rifampin, ethambutol, and streptomycin. Thirty-one clinical isolates and 30 challenge strains provided by the Centers for Disease Control and Prevention (CDC) were tested by MGIT AST SIRE using 2 methods of inoculum preparation, and results were compared with those of the method of proportion, which was considered the reference method. Clinical isolates for which the results of the 2 methods were discordant also were tested at 2 reference laboratories. Based on data from our site and the reference laboratories, agreement rates between initial MGIT AST SIRE results and the method of proportion for the clinical isolates with the inoculum prepared from a McFarland equivalent and from a positive MGIT tube, respectively, were 100% and 96.8% for isoniazid, 100% and 100% for rifampin, 96.8% and 100% for ethambutol, and 100% and 100% for streptomycin, excluding the isolate for which the discordant streptomycin result could not be resolved. For the 30 challenge isolates, agreement rates between MGIT AST SIRE and expected results and between method of proportion and expected results, respectively, were 96.7% and 93.3% for isoniazid, 93.3% and 100% for rifampin, 83. 3% and 100% for ethambutol, and 93.3% and 100% for streptomycin. For the clinical isolates, the mean time to an MGIT AST SIRE result of susceptible was 6.15 +/- 0.13 days (range, 5-8 days). For a result of resistant, the mean time overall was 5.00 +/- 0.24 days (range, 3-8 days). These data suggest that the MGIT AST SIRE system, using either method of inoculum preparation, is an acceptable alternative to the BACTEC 460 TB method of susceptibility testing of clinical isolates of M tuberculosis to isoniazid, rifampin, ethambutol, and streptomycin. Reasons for the lower agreement with the CDC challenge isolates should be investigated. Further evaluation of the MGIT AST SIRE system using a concentration of isoniazid equivalent to the higher concentration tested by the method of proportion would be useful, because the decision concerning use of this agent generally is based on the susceptibility test result at the higher concentration.